Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00540514 · ClinicalTrials.gov registry record · Phase 3

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

A Phase 3 study of Non-Small-Cell Lung Carcinoma, sponsored by Celgene.

Completed
Registry status
Phase 3
Development phase
1,052
Enrollment target
20
Study locations

NCT00540514 is a Phase 3 study of Non-Small-Cell Lung Carcinoma that has completed, run by Celgene. The registered enrollment target is 1,052 participants, above the 201-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (423% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00540514, a Phase 3 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 3
Development phase
1,052 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).

Conditions Studied

Non-Small-Cell Lung Carcinoma

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG Albumin-bound paclitaxel

Study Locations (20)

California

  • Pacific Cancer Medical Center, Inc. - Anaheim
  • Comprehensive Blood and Cancer Center - Bakersfield
  • Southwest Cancer Care - Escondido
  • Robert A. Moss, MD, FACP, Inc. - Fountain Valley
  • Pacific Shores Medical Group - Long Beach
  • Ventura County Hematology-Oncology Specialists - Oxnard
  • Comprehensice Cancer Ctr. - Palms Springs

Arkansas

  • Genesis Cancer Center- Hot Springs - Hot Springs
  • Little Rock Hematology Oncology Associates - Little Rock

Florida

  • Gulf Coast Oncology Associates - St. Petersburg
  • Lake County Oncology and Hematology, PA - Tavares

Maine

  • Mercy Hospital - Portland
  • Maine Center for Cancer Medicine - Scarborough

Alabama

  • Clearview Cancer Institute Oncology Specialties, P.C. - Huntsville

Georgia

  • Phoebe Cancer Center - Albany

Kansas

  • Cancer Center of Kansas - Wichita

Kentucky

  • Kentuckiana Cancer Institute, PLLC - Louisville

Trial Details

FieldValue
Enrollment Target 1,052 participants
Start Date 2007-11-01
Est. Completion 2013-02-01
Phase Phase 3

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00540514

The ClinicalTrials.gov registry entry for NCT00540514 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,052 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 201-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (423% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT00540514 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arkansas, Florida.

Frequently Asked Questions

What is clinical trial NCT00540514 about?

NCT00540514 is a clinical study titled "Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).

What is the current status of trial NCT00540514?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,052 participants. The study started on 2007-11-01. Estimated completion is 2013-02-01.

What conditions does trial NCT00540514 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.

What interventions are being tested in trial NCT00540514?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Albumin-bound paclitaxel (DRUG).

Who is sponsoring clinical trial NCT00540514?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00540514 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small-Cell Lung Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.